Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Shionogi acquires rare disease biotech IntraBio in $2 billion deal

Shionogi acquires rare disease biotech IntraBio in $2 billion deal

Money Moves

The purchase adds AQNEURSA, the first approved treatment for ataxia-telangiectasia, and follows Shionogi's April buy of an ALS drug

2 days ago: Shionogi announces $2 billion purchase of IntraBio

Overview

Updated 1 hour ago

Shionogi agreed to pay $2 billion for IntraBio, a Texas biotech whose single marketed drug treats two inherited neurological disorders. The deal, announced October 5, hands the Osaka-based drugmaker a product that weeks earlier became the first approved treatment for ataxia-telangiectasia, a rare and fatal genetic disease.

The acquisition is Shionogi's second major bet on rare disease in six months. In April it paid $2.5 billion for global rights to edaravone, an ALS treatment sold as Radicava, marking a shift for a company long known as an antibiotics maker. Closing is expected between November and December 2026, pending antitrust review.

Why it matters

The deal gives patients with two ultrarare conditions their first approved drugs and cements Shionogi's conversion from antibiotics specialist to rare disease player.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$2B
Acquisition price
Upfront consideration for all outstanding IntraBio shares, payable by Shionogi Inc.
$68M
IntraBio's 2025 net sales
All of it from AQNEURSA, the company's only marketed drug; IntraBio posted a $35.8 million net loss on that revenue.
2
FDA-approved indications for AQNEURSA
Niemann-Pick disease type C (2024) and ataxia-telangiectasia (September 2026); European approval covers NPC only so far.
$2.5B
Shionogi's April deal for edaravone
Paid Tanabe Pharma for global rights to the ALS drug Radicava, plus a potential royalty on future sales.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Isao Teshirogi
Isao Teshirogi
Chief executive officer, Shionogi & Co.
Overseeing Shionogi's push into rare disease
 Nathan McCutcheon
Nathan McCutcheon
President and chief executive, Shionogi Inc.
Will lead integration of IntraBio as a subsidiary

Organizations Involved

Shionogi & Co.
Shionogi & Co.
Pharmaceutical company
Acquiring IntraBio through its U.S. subsidiary

An Osaka-based drugmaker, historically known for antibiotics and anti-infective drugs, now buying into rare disease.
IntraBio Inc.
IntraBio Inc.
Biopharmaceutical company
To become a wholly owned subsidiary of Shionogi Inc.

An Austin, Texas biotech that developed AQNEURSA, the first approved treatment for ataxia-telangiectasia.

Timeline

2015 October 2026

6 events Latest: 2 days ago
Tap a bar to jump to that date

  1. Shionogi announces $2 billion purchase of IntraBio

    Latest Deal

    Board resolves to acquire all IntraBio shares through Shionogi Inc.; closing expected November to December 2026.

  2. FDA approves AQNEURSA for ataxia-telangiectasia

    Regulatory

    First and only approved treatment for ataxia in A-T patients. EMA review for the same use is ongoing.

  3. Shionogi buys edaravone rights for $2.5 billion

    Deal

    Acquires global rights to the ALS drug Radicava from Tanabe Pharma, adding about $700 million in annual sales.

  4. European Medicines Agency approves AQNEURSA for NPC

    Regulatory

    Approved in the EU alone or with miglustat for neurological symptoms of Niemann-Pick disease type C.

  5. FDA approves AQNEURSA for Niemann-Pick type C

    Regulatory

    First approval for the drug, covering neurological manifestations of NPC in adults and children weighing at least 15 kg.

  6. IntraBio founded in Austin

    Company

    Biotech launched to develop levacetylleucine for neurodegenerative diseases, based on Oxford and Munich research.

Scenarios

1

Shionogi closes IntraBio purchase by end of 2026

Likely Resolves by End of 2026

Discussed by: Shionogi's own timetable, which targets a November-December 2026 closing

The companies see no obstacle to closing this year. Antitrust waiting periods in the U.S. and other relevant countries expire, regulatory clearances come through, and Shionogi Inc. takes ownership of all IntraBio shares, adding AQNEURSA and IntraBio's pipeline to its books.

2

Regulatory review delays closing into 2027

Possible Resolves by Q1 2027

Discussed by: Shionogi, which notes the deal depends on competition-law waiting periods and regulatory approvals

A jurisdiction asks for more information or an extended review, pushing the closing past December 2026. Given both companies' modest size in the deals they compete in, a full block is unlikely, but a slipped timetable is possible in markets where review is slow.

3

AQNEURSA wins European approval for ataxia-telangiectasia

Possible Resolves by Q2 2027

Discussed by: IntraBio and Shionogi, which confirmed EMA review is underway

The European Medicines Agency, which approved AQNEURSA for Niemann-Pick type C in January 2026, follows the FDA's September decision and extends the drug's label to ataxia in A-T patients. This would open a second major market and settle the drug's European footprint under new ownership.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

January 2019

Takeda acquires Shire (2019)

Takeda, Japan's biggest drugmaker, closed a roughly $62 billion takeover of Dublin-based Shire, the largest foreign acquisition ever by a Japanese company. Shire specialized in rare diseases, with treatments for hemophilia, Fabry disease, and other orphan conditions.

Then

Takeda took on heavy debt and restructured, selling non-core units to pay it down.

Now

Takeda became one of the world's leading rare disease companies, showing that scale in orphan drugs can justify enormous acquisition premiums.

Why this matters now

It is the template for a Japanese pharma buying its way into rare disease with a multibillion-dollar deal. Shionogi's IntraBio and edaravone purchases follow the same playbook at smaller scale.

April 2011

Sanofi acquires Genzyme (2011)

Sanofi bought Genzyme for about $20 billion after a hostile takeover battle that dragged on for eight months. Genzyme had pioneered enzyme replacement therapy for rare lysosomal storage diseases, including Cerezyme for Gaucher disease.

Then

Sanofi paid a premium of roughly 60% over Genzyme's pre-offer share price to close the deal.

Now

The purchase made Sanofi a major rare disease player and established that approved orphan drugs command rich prices from big pharma.

Why this matters now

Like Shionogi with AQNEURSA, Sanofi paid well above the target's commercial value to acquire an approved drug and the expertise behind it. Ultra-rare disease therapies justify outsize acquisition multiples because of pricing power and thin competition.

Sources

(5)
Shionogi Inc. BioPharma Dive Fierce Pharma GEN DLA Piper